|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ricci-Vitiani L, Fabrizi E, Palio E and De
Maria R: Colon cancer stem cells. J Mol Med (Berl). 87:1097–1104.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnston PG and Kaye S: Capecitabine: A
novel agent for the treatment of solid tumors. Anticancer Drugs.
12:639–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, et
al: Phase III multicenter randomized trial of oxaliplatin added to
chronomodulated fluorouracil-leucovorin as first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 18:136–147. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicenter randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu X and Xiao H: MiRNAs modulate the drug
response of tumor cells. Sci China C Life Sci. 9:797–801. 2009.
View Article : Google Scholar
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Simerzin A, Zorde-Khvalevsky E, Rivkin M,
Adar R, Zucman-Rossi J, Couchy G, Roskams T, Govaere O, Oren M,
Giladi H and Galun E: The liver-specific microRNA-122*, the
complementary strand of microRNA-122, acts as a tumor suppressor by
modulating the p53/mouse double minute 2 homolog circuitry.
Hepatology. 64:1632–1636. 2016. View Article : Google Scholar
|
|
16
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR-145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang M, Ren D, Guo W, Wang Z, Huang S, Du
H, Song L and Peng X: Loss of miR-100 enhances migration, invasion,
epithelial-mesenchymal transition and stemness properties in
prostate cancer cells through targeting Argonaute 2. Int J Oncol.
45:362–372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sahu N, Stephan JP, Cruz DD, Merchant M,
Haley B, Bourgon R, Classon M and Settleman J: Functional screening
implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance
to cancer drugs. Nat Commun. 7:123512016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Chen Y and Chen Z: MiR-125a/b
regulates the activation of cancer stem cells in
paclitaxel-resistant colon cancer. Cancer Invest. 31:17–23. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Talmon G and Wang J: MicroRNA-587
antagonizes 5-FU-induced apoptosis and confers drug resistance by
regulating PPP2R1B expression in colorectal cancer. Cell Death Dis.
6:e18452015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Chen Y, Hao L, Hou A, Chen X, Li
Y, Wang R, Luo P, Ruan Z, Ou J, et al: Macrophages induce
resistance to 5-fluorouracil chemotherapy in colorectal cancer
through the release of putrescine. Cancer Lett. 381:305–313. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Du C, Huang D, Peng Y, Yao Y, Zhao Y, Yang
Y, Wang H, Cao L, Zhu WG and Gu J: 5-Fluorouracil targets histone
acetyltransferases p300/CBP in the treatment of colorectal cancer.
Cancer Lett. 400:183–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goh AM, Coffill CR and Lane DP: The role
of mutant p53 in human cancer. J Pathol. 223:116–126. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alam SK, Yadav VK, Bajaj S, Datta A, Dutta
SK, Bhattacharyya M, Bhattacharya S, Debnath S, Roy S, Boardman LA,
et al: DNA damage-induced ephrin-B2 reverse signaling promotes
chemoresistance and drives EMT in colorectal carcinoma harboring
mutant p53. Cell Death Differ. 23:707–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deschoemaeker S, Di Conza G, Lilla S,
Martín-Pérez R, Mennerich D, Boon L, Hendrikx S, Maddocks OD, Marx
C, Radhakrishnan P, et al: PHD1 regulates p53-mediated colorectal
cancer chemoresistance. EMBO Mol Med. 7:1350–1365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okamura S, Arakawa H, Tanaka T, Nakanishi
H, Ng CC, Taya Y, Monden M and Nakamura Y: p53DINP1, a
p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell.
8:85–94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin J, Luo M, Qian H and Chen W:
Upregulated miR-182 increases drug resistance in cisplatin-treated
HCC cell by regulating TP53INP1. Gene. 538:342–347. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harrington HA, Ho KL, Ghosh S and Tung KC:
Construction and analysis of a modular model of caspase activation
in apoptosis. Theor Biol Med Model. 5:262008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sidi S, Sanda T, Kennedy RD, Hagen AT,
Jette CA, Hoffmans R, Pascual J, Imamura S, Kishi S, Amatruda JF,
et al: Chk1 suppresses a caspase-2 apoptotic response to DNA damage
that bypasses p53, Bcl-2, and caspase-3. Cell. 133:864–877. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsang WP and Kwok TT: Let-7a microRNA
suppresses therapeutics-induced cancer cell death by targeting
caspase-3. Apoptosis. 13:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang CJ, Hsu CC, Chang CH, Tsai LL, Chang
YC, Lu SW, Yu CH, Huang HS, Wang JJ, Tsai CH, et al: Let-7d
functions as novel regulator of epithelial-mesenchymal transition
and chemoresistant property in oral cancer. Oncol Rep.
26:1003–1010. 2011.PubMed/NCBI
|
|
36
|
Di Fazio P, Montalbano R, Neureiter D,
Alinger B, Schmidt A, Merkel AL, Quint K and Ocker M:
Downregulation of HMGA2 by the pan-deacetylase inhibitor
panobinostat is dependent on hsa-let-7b expression in liver cancer
cell lines. Exp Cell Res. 318:1832–1843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu C, Xie S, Song C, Huang L and Jiang Z:
Lin28 mediates cancer chemotherapy resistance via regulation of
miRNA signaling. Hepatogastroenterology. 61:1138–1141.
2014.PubMed/NCBI
|
|
38
|
Sugimura K, Miyata H, Tanaka K, Hamano R,
Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori
M and Doki Y: Let-7 expression is a significant determinant of
response to chemotherapy through the regulation of IL-6/STAT3
pathway in esophageal squamous cell carcinoma. Clin Cancer Res.
18:5144–5153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu J, Li S, Jia W, Deng H, Chen K, Zhu L,
Yu F and Su F: Reduced Let-7a is associated with chemoresistance in
primary breast cancer. PLoS One. 10:e01336432015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maffioletti E, Cattaneo A, Rosso G, Maina
G, Maj C, Gennarelli M, Tardito D and Bocchio-Chiavetto L:
Peripheral whole blood microRNA alterations in major depression and
bipolar disorder. J Affect Disord. 200:250–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Punga T, Bartoccioni E, Lewandowska M,
Damato V, Evoli A and Punga AR: Disease specific enrichment of
circulating let-7 family microRNA in MuSK+ myasthenia gravis. J
Neuroimmunol. 292:21–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Satoh J, Kino Y and Niida S: MicroRNA-Seq
data analysis pipeline to identify blood biomarkers for Alzheimer's
disease from public data. Biomark Insights. 10:21–31. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Damanakis AI, Eckhardt S, Wunderlich A,
Roth S, Wissniowski TT, Bartsch DK and Di Fazio P: MicroRNAs let7
expression in thyroid cancer: Correlation with their deputed
targets HMGA2 and SLC5A5. J Cancer Res Clin Oncol. 142:1213–1220.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lu ZM, Lin YF, Jiang L, Chen LS, Luo XN,
Song XH, Chen SH and Zhang SY: Micro-ribonucleic acid expression
profiling and bioinformatic target gene analyses in laryngeal
carcinoma. Onco Targets Ther. 7:525–533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pathak S, Meng WJ, Nandy SK, Ping J,
Bisgin A, Helmfors L, Waldmann P and Sun XF: Radiation and SN38
treatments modulate the expression of microRNAs, cytokines and
chemokines in colon cancer cells in a p53-directed manner.
Oncotarget. 6:44758–44780. 2015. View Article : Google Scholar : PubMed/NCBI
|
